{"id":2830,"date":"2026-03-18T13:18:04","date_gmt":"2026-03-18T06:18:04","guid":{"rendered":"https:\/\/naviva.com.vn\/?p=2830"},"modified":"2026-04-13T17:13:07","modified_gmt":"2026-04-13T10:13:07","slug":"the-mav-06-strain-varicella-vaccine-reinforces-immunity-in-children-with-a-prior-history-of-varicella-infection","status":"publish","type":"post","link":"https:\/\/naviva.com.vn\/en\/the-mav-06-strain-varicella-vaccine-reinforces-immunity-in-children-with-a-prior-history-of-varicella-infection","title":{"rendered":"The MAV\/06 strain varicella vaccine reinforces immunity in children with a prior history of varicella infection"},"content":{"rendered":"

Varicella is a common infectious disease with a high propensity for outbreaks among pediatric populations in many countries worldwide, including Vietnam.<\/b><\/span><\/p>\n

\"\"<\/a>According to the WHO and the America CDC, varicella vaccination in children with a prior history of infection is considered safe. <\/span>Photo: Naviva Group<\/span><\/i><\/span><\/p>\n

Live attenuated varicella vaccines have been validated as an effective and durable preventive measure; among these, the MAV\/06 strain has increasingly attracted attention for its favorable safety profile and its ability to induce stable, long-lasting immunity.<\/span><\/p>\n

In clinical practice, whether a child with a prior history of varicella requires vaccination remains a common question raised by healthcare professionals.<\/span><\/p>\n

To address this, it is essential to distinguish between immunity acquired through natural infection and vaccine-induced immunity.<\/span><\/p>\n

Following varicella infection, most children develop immunity to the varicella-zoster virus (VZV); however, the level of protection is variable and depends on factors such as disease severity, age at infection, and overall health status.<\/span><\/p>\n

Children who experience very mild disease or are infected at an early age may develop a weaker and less durable immune response; in addition, some cases may be misdiagnosed, leading to uncertainty regarding prior infection history [1].<\/span><\/p>\n

Numerous studies have reported a risk of varicella recurrence when immunity wanes, particularly in children who previously had mild disease associated with low antibody levels.<\/span><\/p>\n

The US CDC also confirms that the varicella-zoster virus (VZV) remains latent in nerve ganglia and may reactivate when immunity declines, resulting in herpes zoster (shingles) [1].<\/span><\/p>\n

In this context, varicella vaccination serves as an important tool to reinforce immunity. The live attenuated varicella vaccine derived from the MAV\/06 strain has been developed to effectively stimulate a robust immune response.<\/span><\/p>\n

Preclinical and clinical data demonstrate that the MAV\/06 strain induces a robust anti-VZV IgG antibody response while also activating cell-mediated immunity\u2014a key factor in controlling latent viral infection. Protective efficacy is estimated at approximately 80\u201390% against varicella of all severities and exceeds 95% for severe cases [2,3,4].<\/span><\/p>\n

According to the World Health Organization and the US CDC, varicella vaccination in children with a prior history of infection is considered safe. Post-vaccination reactions are generally mild and transient, with no evidence of viral reactivation, herpes zoster, or any serious adverse events reported [3,4].<\/span><\/p>\n

Both the WHO\u00a0 and the CDC recommend varicella vaccination in cases of uncertain infection history, very mild prior disease, infection at an early age, or when long-term immune protection needs to be reinforced [5].<\/span><\/p>\n

The MAV\/06 strain varicella vaccine \u2013 Barycela serves as a safe and effective immunological booster, contributing to sustained protection and long-term pediatric health.<\/span><\/p>\n\n\n\n
BARYCELA Inj., a next-generation varicella vaccine developed by GC Biopharma from the MAV\/06 strain, demonstrates immunogenicity and safety comparable to Oka strain\u2013based vaccines and can be administered in accordance with the current two-dose schedule [10].<\/span><\/p>\n

Recommended Two-Dose Schedule for Optimal Immunity<\/span><\/p>\n

Children aged 12 months to 12 years:<\/span><\/p>\n